Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanouil Fokas

Showing results (131-140 of 158) with videos related to

Pageof 16
Sort By:
International Journal of Cancer|March 15, 2019
Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trialMarkus Diefenhardt, Ralf-Dieter Hofheinz, Daniel Martin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 FallacyAlexander D Sherry, Pavlos Msaouel, Zachary R McCaw, et al.
Cancer Research|February 2, 2022
Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes MetastasisEiman Elwakeel, Mirko Brüggemann, Jessica Wagih, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2024
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trialsEmmanouil Fokas, Hannah Williams, Markus Diefenhardt, et al.
The Lancet. Gastroenterology & Hepatology|May 10, 2025
Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trialCihan Gani, Emmanouil Fokas, Bülent Polat, et al.
Clinical and Translational Radiation Oncology|May 19, 2020
RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trialDaniel Martin, Panagiotis Balermpas, Johannes Gollrad, et al.
JAMA Surgery|June 7, 2018
Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical TrialJulia Kitz, Emmanouil Fokas, Tim Beissbarth, et al.
Oncotarget|October 27, 2016
Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effectEsther A Kleibeuker, Emmanouil Fokas, Philip D Allen, et al.
International Journal of Cancer|July 17, 2015
CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)Panagiotis Balermpas, Franz Rödel, Claus Rödel, et al.
Cancer Medicine|March 25, 2018
Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK)Stephanie E Combs, Maximilian Niyazi, Sebastian Adeberg, et al.
Pageof 16

Showing results (131-140 of 158) with videos related to

Sort By:
Pageof 16
International Journal of Cancer|March 15, 2019
Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trialMarkus Diefenhardt, Ralf-Dieter Hofheinz, Daniel Martin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 FallacyAlexander D Sherry, Pavlos Msaouel, Zachary R McCaw, et al.
Cancer Research|February 2, 2022
Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes MetastasisEiman Elwakeel, Mirko Brüggemann, Jessica Wagih, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2024
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trialsEmmanouil Fokas, Hannah Williams, Markus Diefenhardt, et al.
The Lancet. Gastroenterology & Hepatology|May 10, 2025
Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trialCihan Gani, Emmanouil Fokas, Bülent Polat, et al.
Clinical and Translational Radiation Oncology|May 19, 2020
RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trialDaniel Martin, Panagiotis Balermpas, Johannes Gollrad, et al.
JAMA Surgery|June 7, 2018
Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical TrialJulia Kitz, Emmanouil Fokas, Tim Beissbarth, et al.
Oncotarget|October 27, 2016
Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effectEsther A Kleibeuker, Emmanouil Fokas, Philip D Allen, et al.
International Journal of Cancer|July 17, 2015
CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)Panagiotis Balermpas, Franz Rödel, Claus Rödel, et al.
Cancer Medicine|March 25, 2018
Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK)Stephanie E Combs, Maximilian Niyazi, Sebastian Adeberg, et al.
Pageof 16